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ABSTRACT
Guidelines for the management of atherosclerotic cardiovascular disease (ASCVD) recommend the
use of risk stratification models to identify patients most likely to benefit from cholesterol-lowering
and other therapies. These models have differential performance across race and gender groups with
inconsistent behavior across studies, potentially resulting in an inequitable distribution of beneficial
therapy. In this work, we leverage adversarial learning and a large observational cohort extracted
from electronic health records (EHRs) to develop a "fair" ASCVD risk prediction model with reduced
variability in error rates across groups. We empirically demonstrate that our approach is capable
of aligning the distribution of risk predictions conditioned on the outcome across several groups
simultaneously for models built from high-dimensional EHR data. We also discuss the relevance of
these results in the context of the empirical trade-off between fairness and model performance.
1 Introduction
Atherosclerotic cardiovascular disease (ASCVD), which includes heart attack, stroke, and fatal coronary heart disease,
is a major cause of mortality and morbidity worldwide, as well as in the U.S., where it contributes to 1 in 3 of all
deaths–many of which are preventable [1]. In deciding whether to prescribe cholesterol-lowering therapies to prevent
ASCVD, physicians are often guided by risk estimates yielded by the Pooled Cohort Equations (PCEs). The PCEs
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provide a proportional hazards model [2] that leverages nine clinical measurements to predict the 10-year risk of a first
ASCVD event. However this model has been found to overestimate risk for female patients [3], Chinese patients [4]
or globally [5], as well as also underestimate risk for other groups such as Korean women [6]. Such mis-estimation
results in an inequitable distribution of the benefits and harms of ASCVD risk scoring, because incorrect risk estimates
can expose patients to substantial harm through both under- or over-treatment; potentially leading to preventable
cardiovascular events or side effects from unnecessary therapy, respectively.
The inability of the PCEs to generalize to diverse cohorts likely owes to both under-representation of minority
populations in the cohorts used to develop the PCEs and shifts in medical practice and lifestyle patterns in the decades
since data collection for those cohorts. In attempting to correct for these patterns, one recent study [5] updated the
PCEs using data from contemporary cohorts and demonstrated that doing so reduced the number of minority patients
incorrectly misclassified as being high or low risk. Similar results were observed in the same study with an approach
using an elastic net classifier, rather than a proportional hazards model. However, neither approach is able to explicitly
guarantee an equitable distribution of mis-estimation across relevant subgroups, particularly for race- and gender-based
subgroups.
To account for under-represented minorities and to take advantage of the wider variety of variables made available
in electronic health records (EHRs), we derive a large and diverse modern cohort from EHRs to learn a prediction
model for ASCVD risk. Furthermore, we investigate the extent to which we can encode algorithmic notions of fairness,
specifically equality of odds [7], into the model to encourage an equitable distribution of performance across populations.
To the best of our knowledge, our effort is the first to explore the extent to which this formal fairness metric is achievable
for risk prediction models built using high-dimensional data from the EHR. We show that while it is feasible to develop
models that achieve equality of odds, we emphasize that this process involves trade-offs that must be assessed in a
broader social and medical context [8].
2 Background and Related Work
2.1 ASCVD Risk Prediction and EHRs
The PCEs are based on age, gender, cholesterol levels, blood pressure, and smoking and diabetes status and were
developed by pooling data from five large U.S. cohorts [2] composed of white and black patients, with white patients
constituting a majority. Recently, attempts [5] were made to update the PCEs to improve model performance for race-
and gender-based subgroups using elastic net regression and data from modern prospective cohorts. However, this
effort focused on demographic groups and variables already used to develop the PCEs and did not consider other
populations or clinical measurements. The increasing adoption of EHRs offers opportunities to deploy and refine
ASCVD risk models. Efforts have recently been undertaken to apply and refine existing models, including the PCEs and
the Framingham score, to large EHR-derived cohorts and characterize their performance in certain subgroups [9, 10].
Beyond ASCVD risk prediction, there exist many recent works that develop prediction models with EHRs, which are
reviewed in [11].
2.2 Fair Risk Prediction
We consider the case where supervised learning is used to estimate a function f(X) that approximates the conditional
distribution p(Y |X), given N samples {xi, yi, zi}Ni=1 drawn from the distribution p(X,Y, Z). We take X ∈ X = Rm
to correspond to a vector representation of the medical history extracted from the EHR prior to a patient-specific index
time ti; Y ∈ Y = {0, 1} to be a binary label, which for patient i, indicates the presence of the outcome observed in the
EHR in the time frame [ti, ti + wi], where wi is a parameter specifying the amount of time following the index time
used to derive the outcome; and Z ∈ Z = {0, . . . , k − 1} indicates a sensitive attribute, such as race, gender, or age,
with k groups. The output of the learned function f(X) ∈ [0, 1] is then thresholded with respect to a value T to yield a
prediction Yˆ ∈ {0, 1}.
One standard metric for assessing the fairness of a classifier with respect to a sensitive attribute Z is demographic parity
[12], which evaluates the independence between Z and the prediction Yˆ . Formally, the demographic parity criterion
may be expressed as
p(Yˆ |Z = Zi) = p(Yˆ |Z = Zj)∀Zi, Zj ∈ Z. (1)
However, optimizing for demographic parity is of limited use for clinical risk prediction, because doing so may preclude
the model from considering relevant clinical features associated with the sensitive attribute and the outcome, thus
decreasing the performance of the model for all groups [13].
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Another related metric is equality of odds [7], which stipulates that the prediction Yˆ be conditionally independent of Z,
given the true label Y . Formally, satisfying equality of odds implies that
p(Yˆ |Z = Zi, Y = Yk) = p(Yˆ |Z = Zj , Y = Yk)∀Zi, Zj ∈ Z;Yk ∈ Y. (2)
From this, it can be seen that, if equality of odds is achieved, then for a fixed threshold T , both the false positive (FPR)
and false negative rates (FNR) are equal across all pairs of groups defined by Z. Compared to demographic parity,
equality of odds is more appropriate in a clinical setting, since it does not necessarily preclude the learning of the
optimal predictor in the case that a true relationship between sensitive attribute and the outcome exists [7].
Furthermore, this definition can be extended to the case of a continuous risk score by requiring that
p(f(X)|Z = Zi, Y = Yk) = p(f(X)|Z = Zj , Y = Yk)∀Zi, Zj ∈ Z;Yk ∈ Y. (3)
In this case, the distribution of the predicted probability of the outcome conditioned on whether the event occurred
or not should be matched across groups of a sensitive attribute. Formulation 3 is stronger than 2 since it implies that
equality of odds is achieved for all possible thresholds, thus requiring that the same ROC curve be attained for all
groups. This is desirable since it provides the end-user the ability to freely adjust the decision threshold of the model
without violating equality of odds.
Finally, we also note that satisfying equality of odds for a continuous risk score may be reduced to the problem of
minimizing a divergence over each pair (Zi, Zj) of distributions referenced in equation (3). Adversarial learning
procedures [14] are well-suited to this problem in that they provide a flexible framework for minimizing the divergence
over distributions parameterized by neural networks. As such, several related works [15, 16, 17, 18] have demonstrated
the benefit of augmenting a classifier with an adversarial discriminator in order to align the distribution of predictions
for satisfying fairness constraints.
2.3 Approaches for Achieving Fairness
Despite considerable interest in the ethical implications of implementing machine learning in healthcare [19, 20],
relatively little work exists characterizing the extent to which risk prediction models developed with EHR data satisfy
formal fairness constraints.
Adversarial approaches for satisfying fairness constraints (in the form of demographic parity) have been explored
in several recent works in non-healthcare domains. One approach, [17], in the context of image anonymization,
demonstrated that representations satisfying demographic parity could be learned by augmenting a predictive model
with both an autoencoder and an adversarial component. The adversarial approach to fairness was further investigated
by [16] with a gradient reversal objective for data that is imbalanced in the distribution of both the outcome and in the
sensitive attribute.
In attempting to address the limitations of demographic parity as a metric, [7] introduced equality of odds as an
alternative and devised post-processing methods to achieve it for fixed-threshold classifiers. Recently, [15] and [18]
generalized the adversarial framework to achieve equality of odds by providing the discriminator access to the value of
the outcome.
Both demographic parity and equality of odds are referred to as group fairness metrics since they are concerned with
encouraging an invariance of some property of a classifier over groups of a sensitive attribute. While straightforward to
compute and reason about, optimizing for these metrics may produce models that are discriminatory over structured
subgroups within and across groups of sensitive attributes, constituting a form of fairness gerrymandering [21]. The
competing notion of individual fairness [12] and may be able to address these concerns by assessing whether a model
produces similar outputs for similar individuals. However, this notion is often of limited practical use due to the
challenges of developing a domain-specific similarity metric that encodes desired notions of fairness.
Recent efforts [22] have investigated an alternative to both group and individual fairness metrics with a process that audits
a classifier to discover subgroups for which the model is under-performing and iteratively improve model performance
for those groups, ultimately resulting in a non-negative change in model performance for all computationally-identifiable
subgroups.
The closest related work examining the fairness of risk prediction models in healthcare is [23], which, in the context of
mortality prediction in intensive care units, argued that any trade-off between model performance and fairness across
subgroups is undesirable. They propose that the prediction error should be decomposed in terms of bias, variance, and
noise and that the relative contribution of these terms be used to guide additional data collection.
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Table 1: Cohort characteristics. The number of patients extracted, the incidence of the ASCVD outcome and the average
length of follow-up for each subgroup are shown.
Group Count ASCVD Incidence Follow-up Length (Years)
Asian 34,156 0.0144 2.83
Black 9,018 0.0271 2.76
Hispanic 21,587 0.0152 2.81
Other 19,100 0.013 2.78
Unknown 30,300 0.00512 2.96
White 136,348 0.0141 2.93
Female 154,266 0.0116 2.87
Male 96,074 0.0167 2.93
40-55 117,510 0.00603 2.95
55-65 64,477 0.0128 2.92
65-75 44,149 0.02 2.83
75+ 24,373 0.0398 2.64
All 250,509 0.0135 2.89
Table 2: Distribution alignment metrics. We report the coefficient of variation (CV; the ratio of the standard deviation to
the mean) of the false positive rate (FPR, CV) and false negative rate (FNR, CV) at a fixed decision threshold of 0.075
across the race, gender, and age groups. Furthermore, we compute the pairwise earth mover’s distance (EMD) between
distributions of the predicted probabilities of having an ASCVD event, conditioned on the true ASCVD label y for each
group of each sensitive attribute and take the mean.
Race Gender Age
Standard EQrace Standard EQgender Standard EQage
FNR, CV 0.267 0.0437 0.118 0.0072 0.347 0.0426
FPR, CV 0.451 0.563 0.477 0.231 0.927 0.522
Mean EMD | y = 0 0.00905 0.00109 0.0107 0.000983 0.0277 0.00162
Mean EMD | y = 1 0.0264 0.00934 0.0144 0.00259 0.0363 0.0189
3 Methods
3.1 The Dataset and Cohort Definition
We extract records from the Stanford Medicine Research Data Repository [24], a clinical data warehouse containing
records on roughly three million patients from Stanford Hospital and Clinics and Lucile Packard Children’s Hospital for
clinical encounters occurring between 1990 and 2018. We define a prediction task that resembles the setting in which
the PCEs were developed [2] for the purpose of guiding physician decision-making in ASCVD prevention and construct
a corresponding cohort. As a first step, we identify all patients with at least two clinical encounters over a time span of
at least two years for which they are 40 years or older. Then, for each patient, we randomly select a clinical encounter
from the time span that allows for at least one year of history and one year of follow-up and set the date of the encounter
as the index time ti. Patients with no encounters meeting this criteria are excluded. We further exclude from the cohort
patients with a historical diagnosis of cardiovascular disease (myocardial infarction, stroke, atrial fibrillation, heart
failure) or a prescription of a lipid lowering drug (see supplementary material) in the five years prior to the index time.
We assign a positive ASCVD label if a diagnosis code for an ASCVD event (myocardial infarction, stroke, or fatal
coronary heart disease) is observed at any point in their record following the index time. We consider coronary heart
disease to be fatal if a diagnosis code for coronary heart disease is followed by death within a year.
The patients are randomly partitioned such that 80%, 10%, 10% are used for training, validation, and testing, respectively.
The clinical concepts used to define the exclusion criteria and outcome definition are provided in the supplementary
material.
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3.2 Sensitive Attributes
We consider race, gender, and age as sensitive attributes and assess model performance and fairness with respect to
them. For race, we use both race and ethnicity variables to partition the cohort into six disjoint groups: Asian, Black,
Hispanic, Other, Unknown, and White. Patients not considered Hispanic thus have either a non-Hispanic or unknown
ethnicity. For gender, we partition the cohort into male and female populations. For age, we discretize the age at the
index time into four disjoint groups: 40-55, 55-65, 65-75, and 75+ years, where the intervals are inclusive on the lower
bound and exclusive on the upper bound. A summary of these groups is presented in Table 1.
3.3 Feature Extraction
For feature extraction, we adopt a strategy similar to the one described in [25] to convert time-stamped sequences of
clinical concepts across several domains (i.e., diagnoses, procedures, medication orders, lab tests, clinical encounter
types, departments, and other observations) into a static representation suitable for modeling. For each extracted patient,
we filter the historical record to include only those concepts occurring prior to the index time. We encode as a binary
attribute each unique clinical concept observed in the dataset according to whether that concept was present anywhere
in the patient’s history prior to the prediction time; otherwise, it is absent or missing. Similarly, we do not use the
numeric results of lab tests or vital measurements, but only include the presence of their measurement. In all models,
we include race, gender, and age as features without regards as to whether the variable is treated as sensitive or not.
3.4 Adversarial Learning for Equality of Odds
To develop an ASCVD risk prediction model that satisfies the definition of equality of odds in (3), we consider two
fully-connected neural networks: a classifier f : Rm → R ∈ [0, 1] parameterized by θf that predicts the probability of
the ASCVD outcome Y given data X; and a discriminator g : R × {0, 1} → [0, 1]k parameterized by θg that takes
as input both the logit of the output of f and the value of the true label Y to predict a distribution over the groups
of a sensitive attribute Z. If Lcls and Ladv are the cross-entropy losses of the classifier predictions over Y and the
discriminator predictions over Z, respectively, and λ is a positive scalar, then the training procedure may be described
by alternating between the steps
min
θf
Lcls − λLadv and min
θg
Ladv. (4)
3.5 Model Training and Evaluation
The training procedure is composed of four experiments and thus produces four prediction models. The first model is
trained to predict the risk of ASCVD and does not use adversarial training. The other three models result from separate
training runs in which each of the discrete race, gender, and age variables are considered as sensitive attributes in the
adversarial training procedure. We refer to these four experiments as Standard, EQrace, EQgender, and EQage.
For each model, we compute standard metrics on the entire test set and on each subgroup. Specifically, we report the
area under the receiver operating characteristic curve (AUC-ROC), the area under the precision-recall curve (AUC-PRC),
the Brier score [26] as a measure of calibration, and the false positive and false negative rates (FPR, FNR) at a fixed
threshold of T = 0.075, in keeping with current ASCVD guidelines for the prescription of statin therapy [2, 5]. To
express adherence to the standard equality of odds definition in equation 2, we report the coefficient of variation (i.e.
the ratio of the standard deviation to the mean) of the FPR and FNR at T = 0.075 across the groups of each sensitive
attribute. To assess the distance between the distributions presented in (3), we compute the earth mover’s distance (EMD,
or first Wasserstein distance) between the empirical distributions of the predicted probability of ASCVD conditioned on
whether ASCVD occurred or not for each group of each sensitive attribute in a pairwise fashion and take the mean
within each outcome strata.
For each of the four models, we employ fully-connected feedforwad neural networks composed of layers of fixed
size for both the classifier and discriminator. Hyperparameters were selected separately for each model across 100
iterations of random search over a grid that included the number of classifier and discriminator layers, the size of each
layer, the learning rates of the Adam optimizers [27] applied on θf and θg , the discriminator weight λ, the use of layer
normalization [28] in the classifier and the discriminator, and the use of spectral normalization [29] in the discriminator.
Models we trained for 100 epochs, where each epoch is composed of 100 one hundred randomly sampled batches of
the data. During training, early stopping was performed on the basis of the maximal AUC-ROC on the validation set.
As it is not clear how to best perform model selection for the EQ experiments, we take the model with the highest degree
of distribution alignment on the validation set, computed as the mean of the EMD metrics computed on each outcome
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Table 3: Model performance measured on the test set without stratification for each experimental condition.
Standard EQrace EQgender EQage
AUC-ROC 0.773 0.742 0.743 0.694
AUC-PRC 0.0904 0.083 0.0924 0.0887
Brier Score 0.0143 0.0137 0.0138 0.0136
Table 4: Model performance measured on the test set stratified by group and experimental condition. EQ corresponds to
training for the sensitive attribute corresponding to the subgroup of interest.
AUC-ROC AUC-PRC Brier Score
Stand. EQ Stand. EQ Stand. EQ
Asian 0.726 0.704 0.0775 0.0508 0.0142 0.0133
Black 0.785 0.74 0.244 0.158 0.0294 0.0307
Hispanic 0.721 0.724 0.0811 0.113 0.0157 0.0146
Other 0.783 0.792 0.0887 0.097 0.0133 0.0123
Unknown 0.824 0.77 0.0274 0.0141 0.004 0.00376
White 0.768 0.744 0.0956 0.0914 0.0155 0.015
Female 0.768 0.749 0.0835 0.1 0.0123 0.0119
Male 0.769 0.731 0.104 0.0847 0.0175 0.0169
40-55 0.726 0.689 0.0369 0.0398 0.00661 0.0063
55-65 0.741 0.742 0.0966 0.116 0.0141 0.0131
65-75 0.699 0.672 0.0966 0.0919 0.0209 0.0198
75+ 0.679 0.662 0.135 0.153 0.0408 0.0395
strata, that also achieves an AUC-ROC of greater than 0.7 on the validation set. All training and model development
was performed with the PyTorch library [30].
4 Results
4.1 Cohort Characteristics
The cohort extraction procedure produces a cohort of 250,509 patients having 200,407 features, with 3,388 patients
labeled as positive for ASCVD (Table 1). We note that in this cohort, there are 136,348 white patients, constituting
a majority, and 9,018 black patients. Across race groups, ASCVD rates range from 1.0-2.0%, with the exception of
patients with unknown race, who experience a reduced rate of 0.52%. Furthermore, we observe higher ASCVD rates
for male patients compared to female patients. Finally, ASCVD rates appear to increase with age, with rates ranging
from approximately 0.6% for the 40-55 age group to 4% for patients age 75 or older.
4.2 Distribution Alignment with Adversarial Training
Applying the adversarial training procedure results in a alignment of the distributions of the predicted probability of
ASCVD conditioned on the true outcome label (Figure 1). Without employing a adversarial discriminator, the center of
mass of these distributions appears to depend on the base ASCVD rate in the group. However, these differences largely
disappear when training in an adversarial setting. This results in a substantial reduction in the mean pairwise EMD
between each predictive distribution in both outcome strata for all sensitive attributes (Table 2). Furthermore, we note
that variability in the FPRs and FNRs at a fixed threshold of 0.075 is greatly reduced following adversarial training
(Table 2), indicating that the approach successfully encourages the model predictions to satisfy equality of odds.
The relative lack of success in minimizing the mean pairwise EMD between the conditional predictive distributions
across racial groups that experience ASCVD (Table 2) may be largely explained by the anomalous characteristics of
the group of patients having unknown race. For instance, when using standard training (Standard), the predictive
distribution for both outcome strata for the unknown race group is clearly separated from that of the five groups while
the distributions for those five are mostly aligned (Figure 1). However, when training the model in an adversarial
setting, it appears that the primary effect is to align the predictive distribution for the unknown race group to the region
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Figure 1: Empirical distribution of the predicted probability of developing ASCVD in the followup period conditioned
on whether ASCVD occurred. Plots are stratified by experimental condition (Standard or EQ), true value of the
ASCVD outcome (y = 0 or y = 1), and the variable treated as sensitive (race, gender, or age).
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inhabited by the distributions of the remaining groups while disturbing the relative alignment between the distributions
for those groups.
4.3 The Cost of Fairness
Satisfying equality of odds with an adversarial objective incurs a reduction in AUC-ROC, AUC-PRC, and calibration
for the population at large (Table 3), with the largest negative effects observed when training to adjust for the differences
across age groups (Standard AUC-ROC = 0.773 vs. EQage AUC-ROC = 0.694). This procedure induces a reduction in
AUC-ROC and AUC-PRC for many of the populations assessed (Table 4), with positive effects observed only in the
Hispanic and Other race groups. Furthermore, while exactly satisfying equality of odds implies that the ROC curve be
the same across for each group of a sensitive attribute, the procedure we apply does not empirically produce a model
that achieves the same AUC-ROC on each group.
It has been shown that developing a well-calibrated model is an objective that conflicts with that of satisfying equality
of odds [31, 13]. In our case, we do not observe a trade-off, as the Brier score is reduced, indicating better calibration,
when training for equalized odds both for the aggregate population (3) and for many subgroups (Table 4).
5 Discussion
We have demonstrated the capabilities of adversarial training procedures to encourage the learning of models whose
predictions satisfy equality of odds for high-dimensional EHR data with sensitive attributes of more than two groups. In
a setting such as ASCVD risk prediction, with a clear clinical intervention associated with the prediction, this procedure
ensures that no group bears a disparate burden of mistreatment due to misclassification. However, we note that this
comes at a cost of a reduction in AUC-ROC and AUC-PRC for some subgroups.
5.1 Limitations of the Predictive Model
While using EHR data allowed a high-capacity ASCVD risk prediction model to be trained using a large and diverse
cohort, this model should not be directly compared to the PCEs for several reasons. First, the PCEs estimate ten-year
ASCVD risk, whereas our model estimates risk over a period of at least a year. Furthermore, we cannot rule out the
existence of biases that may lead to differential rates of selection or censoring in our cohort across age, gender, and race
based subgroups, nor can we establish whether the nature of these biases differ from those present in the prospective
cohort studies used to derive the PCEs.
5.2 Moving Beyond Equality of Odds
While we have demonstrated empirically that adversarial learning procedures are capable of encouraging a model to
satisfy equality of odds, the use of this metric as a measure of fairness should be approached with caution. In the case
that there is insufficient information in the training dataset to learn a high performing model for at least one group,
optimizing for this criteria will upper bound the group-level model performance by the performance obtained for the
least-well performing group. In the adversarial learning setting, this reduction in performance for some groups may
be offset by performance gains for groups for which the model performs poorly when trained naively. However, we
observed that if such a benefit exists, it is smaller than the reduction in performance incurred for most groups.
We have not examined the relationship between the errors of the predictive model and notions of long-term utility
when deploying the model clinically. To properly analyze the effect of these errors on utility requires careful causal
modeling of the sequential decision-making process following ASCVD risk prediction while accounting for individual
patient characteristics. We emphasize that while such a process is crucial to evaluate the long-term impact of any
prediction model, it is not possible to properly identify and model that causal process with observational data in the
EHR alone [32]. Additionally, it is unclear that satisfying fairness constraints for a single-step decision, as in ASCVD
risk prediction, aligns with the goal of equitably maximizing long-term utility, as it has been shown that satisfying
fairness constraints for a static decision may actually cause long-term harm in settings where an unconstrained objective
would not [33], particularly if the outcome is measured with bias due to systematic censoring [34]. We find those
approaches [35, 36] that establish causal notions of fairness to be promising directions for future work, as they permit
sequential decision making processes to be studied under the lens of fairness at both the group and individual level.
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6 Conclusion
Existing approaches to ASCVD risk scoring perform poorly for the population at large, with more extreme risk
mis-estimates for minority populations, inadvertently exposing those groups to excess harm. We develop an ASCVD
prediction model using EHR data and show that we can encourage formal notions of fairness by reducing the variability
in the FPR and FNR across groups. It is not yet known to what extent algorithmic notions of fairness align with other
goals, including long-term utility maximization. We hope that our results will serve as an impetus for the community
at large to investigate the fairness-utility trade-off during sequential clinical decision making resulting from fairness
constraints imposed on clinical risk assessments.
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A Clinical concepts used for cohort and outcome definition
A.1 Exclusion Criteria: Cardiovascular Disease
The presence of any of the following ICD9CM codes prior to the index time was used to define historical cardiovascular
disease: 410, 410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11, 410.12, 410.2, 410.20, 410.21, 410.22, 410.3,
410.30, 410.31, 410.32, 410.4, 410.40, 410.41, 410.42, 410.5, 410.50, 410.51, 410.52, 410.6, 410.60, 410.61, 410.62,
410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81, 410.82, 410.9, 410.90, 410.91, 410.92, 411, 411.0, 411.1, 411.8,
411.81, 411.89, 413, 413.0, 413.1, 413.9, 414, 414.0, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06, 414.07,
414.1, 414.10, 414.11, 414.12, 414.19, 414.2, 414.3, 414.4, 414.8, 414.9, 427.31, 428, 428.0, 428.1, 428.2, 428.20,
428.21, 428.22, 428.23, 428.3, 428.30, 428.31, 428.32, 428.33, 428.4, 428.40, 428.41, 428.42, 428.43, 428.9, 430, 431,
432, 432.0, 432.1, 432.9, 433, 433.0, 433.00, 433.01, 433.1, 433.10, 433.11, 433.2, 433.20, 433.21, 433.3, 433.30,
433.31, 433.8, 433.80, 433.81, 433.9, 433.90, 433.91, 434, 434.0, 434.00, 434.01, 434.1, 434.10, 434.11, 434.9, 434.90,
434.91, 436
A.2 Exclusion Criteria: Lipid Lowering Drugs
The presence of any of the following medications from the Antomatical Therapeutic Chemical Classification System
(ATC) in the five years prior to index time was used to exclude patients on the basis of a history of prescription of lipid
lowering drugs: atorvastatin (C10AA05), simvastatin (C10AA01), rosuvastatin (C10AA07), lovastatin (C10AA02),
pitavastatin (C10AA08), fluvastatin (C10AA04), pravastatin (C10AA03), atorvastatin and ezetimibe (C10BA05),
cerivastatin (C10AA06), atorvastatin and amlodipine (C10BX03), lovastatin and nicotinic acid (C10BA01), simvastatin
and ezetimibe (C10BA02), simvastatin and fenofibrate (C10BA04).
A.3 Outcome Definition: ASCVD
The presence of any of the following ICD9CM codes following the index time was used to define ASCVD events
(myocardial infarction and stroke): 410, 410.0, 410.00, 410.01, 410.1, 410.10, 410.11, 410.2, 410.20, 410.21, 410.3,
410.30, 410.31, 410.4, 410.40, 410.41, 410.5, 410.50, 410.51, 410.6, 410.60, 410.61, 410.7, 410.70, 410.71, 410.8,
410.80, 410.81, 410.9, 410.90, 410.91, 430, 431, 433, 433.0, 433.01, 433.1, 433.11, 433.2, 433.21, 433.3, 433.31,
433.8, 433.81, 433.9, 433.91, 434, 434.0, 434.01, 434.1, 434.11, 434.9, 434.91, 436.
Patients were also labeled as positive for ASCVD if one of the following ICD9CM codes indicative of coronary heart
disease was assigned following the index time and death occurred within one year of the diagnosis: 411, 411.0, 411.1,
411.8, 411.81, 411.89, 413, 413.0, 413.1, 413.9, 414, 414.0, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06,
414.07, 414.1, 414.10, 414.11, 414.12, 414.19, 414.2, 414.3, 414.4, 414.8, 414.9
12
